Coloplast A/S Fundamental Analysis
Coloplast A/S (CLPBF) shows weak financial fundamentals with a PE ratio of 39.92, profit margin of 7.50%, and ROE of 14.21%. The company generates $25.8B in annual revenue with moderate year-over-year growth of 3.12%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 47.8/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CLPBF's fundamental strength across five key dimensions:
Efficiency Score
WeakCLPBF struggles to generate sufficient returns from assets.
Valuation Score
ModerateCLPBF shows balanced valuation metrics.
Growth Score
WeakCLPBF faces weak or negative growth trends.
Financial Health Score
ModerateCLPBF shows balanced financial health with some risks.
Profitability Score
WeakCLPBF struggles to sustain strong margins.
Key Financial Metrics
Is CLPBF Expensive or Cheap?
P/E Ratio
CLPBF trades at 39.92 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, CLPBF's PEG of -0.12 indicates potential undervaluation.
Price to Book
The market values Coloplast A/S at 6.53 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 4.63 times EBITDA. This is generally considered low.
How Well Does CLPBF Make Money?
Net Profit Margin
For every $100 in sales, Coloplast A/S keeps $7.50 as profit after all expenses.
Operating Margin
Core operations generate 26.38 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $14.21 in profit for every $100 of shareholder equity.
ROA
Coloplast A/S generates $4.50 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Coloplast A/S generates strong operating cash flow of $6.98B, reflecting robust business health.
Free Cash Flow
Coloplast A/S generates strong free cash flow of $5.54B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $26.74 in free cash annually.
FCF Yield
CLPBF converts 7.80% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
39.92
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.12
vs 25 benchmark
P/B Ratio
Price to book value ratio
6.53
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.76
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.89
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.75
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.14
vs 25 benchmark
ROA
Return on assets percentage
0.05
vs 25 benchmark
ROCE
Return on capital employed
0.18
vs 25 benchmark
How CLPBF Stacks Against Its Sector Peers
| Metric | CLPBF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 39.92 | 29.34 | Worse (Expensive) |
| ROE | 14.21% | 688.00% | Weak |
| Net Margin | 7.50% | -52372.00% (disorted) | Weak |
| Debt/Equity | 1.89 | 0.49 | Weak (High Leverage) |
| Current Ratio | 1.75 | 4.37 | Neutral |
| ROA | 4.50% | -20476.00% (disorted) | Weak |
CLPBF outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Coloplast A/S's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
41.80%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-18.27%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
31.72%
Industry Style: Defensive, Growth, Innovation
High Growth